Development Highlights (GlobeNewswire) - Nov 12, 2025 - "Recruitment of participants into the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies evaluating the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations is ongoing with topline data from both studies expected in the first half of 2026."
Enrollment status • P2 data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology
|